Table II.
Systemic therapy following diagnosis of bone metastases (n=236).
| Treatment | n (%) |
|---|---|
| Chemotherapy typea | |
| None | 149 (63) |
| One line | 46 (20) |
| Two lines | 27 (11) |
| Three lines | 14 (6) |
| Chemotherapy druga | |
| Taxotere | 79 (34) |
| Mitoxantrone | 9 (4) |
| Cabazitaxel | 5 (2) |
| Abiraterone | 28 (12) |
| Enzalutamide | 10 (4) |
| None | 105 (44) |
| Bisphosphonates/denosumab treatment | |
| None | 111 (47) |
| Monthly zoledronic acid | 98 (42) |
| Monthly denosumab | 23 (10) |
| Other bisphosphonate | 4 (2) |
| Overall systemic therapy | |
| None | 94 (40) |
| Bone-targeted | 55 (23) |
| Chemotherapya | 17 (7) |
| Both | 70 (30) |
| Radionuclide therapy | |
| None | 225 (95) |
| Radium-223 | 6 (3) |
| Other | 5 (2) |
a
Includes cytotoxic chemotherapy, abiraterone and enzalutamide.